Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canlitinib vs Chemotherapy in Advanced Esophageal Squamous Cell Carcinoma
NCT06194734Phase 3Recruiting
- Sponsor
- Beijing Konruns Pharmaceutical Co., Ltd.
- Start
- Feb 2024
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of connitinib in Esophageal Squamous Cell Carcinoma (ESCC) (2 arms), sponsored by Beijing Konruns Pharmaceutical Co., Ltd. Primary endpoint: Overall Survival up to 24 months. Started Feb 2024; status: recruiting.
02
Drugs
connitinib
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT06194734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06194734.